Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.

Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…

Article Date

This article is featured on another website.

Go to article
April 24, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, CA — April 24, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant […]

April 24, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, CA — April 24, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]